Drug Trial Radar · NCT02436096
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
Last checked: Nov 20, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
519
Actual
Start
Apr 2015
Primary completion
Sep 2016
Study completion Sep 2016
Sponsor
- Lead sponsor
- Tonix Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 6, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The use of low-dose CBP dosed nightly at bedtime for FM was supported by the results of Tonix' TNX-CY-F202 Phase 2b study (also referred to as the BESTFIT Study). The TNX-CY-F202 study provided evidence that TNX-102 SL 2.8 mg dosed nightly results in beneficial effects upon pain, sleep and other FM symptomatology. The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia.
Conditions
- Fibromyalgia
- Myofascial Pain Syndromes
- Muscular Diseases
- Musculoskeletal Diseases
- Nervous System Diseases
- Neuromuscular Diseases
- Rheumatic Diseases
Interventions
TNX-102 SL Tablet, 2.8mgDrug
Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
Placebo SL TabletDrug
Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients With ≥30% Pain ImprovementTime frame: Day 1, Week 12
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Brandon, Florida
Site not named
DeLand, Florida
Site not named
Lakeland, Florida
Site not named
Ocala, Florida
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Tampa, Florida
Site not named
West Palm Beach, Florida
Site not named
Columbus, Georgia
Site not named
Smyrna, Georgia
Site not named
Evansville, Indiana
Site not named
North Dartmouth, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Jackson, Mississippi
Site not named
Williamsville, New York
Site not named
Cincinnati, Ohio
Site not named
Columbus, Ohio
Site not named
Middleburg Heights, Ohio
Site not named
Medford, Oregon
Site not named
Portland, Oregon
Site not named
Allentown, Pennsylvania
Site not named
Warwick, Rhode Island
Site not named
Greer, South Carolina
Site not named
Mt. Pleasant, South Carolina
Site not named
Dallas, Texas
Site not named
Salt Lake City, Utah
Site not named
Charlottesville, Virginia
Site not named
Norfolk, Virginia
Site not named
Bellevue, Washington
Site not named
Seattle, Washington
Site not named
Kenosha, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.